secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001437749-26-010164
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio signs cGMP manufacturing deal; PH-762 Phase 1b shows 85% pathological response
--------------------------------------------------------------------------------

- Entered cGMP drug product manufacturing agreement with U.S. manufacturer for clinical and commercial supply of PH-762.
- PH-762 Phase 1b trial: 22 patients completed, no dose-limiting toxicities or serious adverse events.
- Pathological response rate across all cohorts ~65%; highest-dose cohort achieved 85% (6 of 7 patients).
- FDA engagement for next-stage clinical development targeted for Q2 2026.
- Cash and equivalents projected to sustain operations into H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926010164/0001437749-26-010164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926010164/phio20260326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-010164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer